Anixa Biosciences, Inc. beat EPS estimates 100% of the time across 2 reported quarters (2 beats, 0 misses), averaging +20.6% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | $-0.10 | $-0.07 | +30.0% | Beat | |
| Q1 FY26 | $-0.09 | $-0.08 | +11.1% | Beat |
Back to ANIX overview · ANIX holders · ANIX KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.